Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt 1.08
ZMH's Cash to Debt is ranked higher than
56% of the 377 Companies
in the Global Medical Devices industry.

( Industry Median: 6.28 vs. ZMH: 1.08 )
ZMH' s 10-Year Cash to Debt Range
Min: 0.05   Max: No Debt
Current: 1.08

Equity to Asset 0.66
ZMH's Equity to Asset is ranked higher than
69% of the 358 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. ZMH: 0.66 )
ZMH' s 10-Year Equity to Asset Range
Min: 0.11   Max: 0.82
Current: 0.66

0.11
0.82
Interest Coverage 14.77
ZMH's Interest Coverage is ranked higher than
53% of the 223 Companies
in the Global Medical Devices industry.

( Industry Median: 205.72 vs. ZMH: 14.77 )
ZMH' s 10-Year Interest Coverage Range
Min: 14.37   Max: 9999.99
Current: 14.77

14.37
9999.99
F-Score: 5
Z-Score: 5.15
M-Score: -2.52
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 22.40
ZMH's Operating margin (%) is ranked higher than
93% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 6.25 vs. ZMH: 22.40 )
ZMH' s 10-Year Operating margin (%) Range
Min: 21.07   Max: 33.34
Current: 22.4

21.07
33.34
Net-margin (%) 16.46
ZMH's Net-margin (%) is ranked higher than
90% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 4.82 vs. ZMH: 16.46 )
ZMH' s 10-Year Net-margin (%) Range
Min: 12.71   Max: 23.87
Current: 16.46

12.71
23.87
ROE (%) 12.08
ZMH's ROE (%) is ranked higher than
85% of the 365 Companies
in the Global Medical Devices industry.

( Industry Median: 5.79 vs. ZMH: 12.08 )
ZMH' s 10-Year ROE (%) Range
Min: 10.34   Max: 190.34
Current: 12.08

10.34
190.34
ROA (%) 7.94
ZMH's ROA (%) is ranked higher than
86% of the 380 Companies
in the Global Medical Devices industry.

( Industry Median: 3.09 vs. ZMH: 7.94 )
ZMH' s 10-Year ROA (%) Range
Min: 6.72   Max: 30.02
Current: 7.94

6.72
30.02
ROC (Joel Greenblatt) (%) 40.08
ZMH's ROC (Joel Greenblatt) (%) is ranked higher than
88% of the 379 Companies
in the Global Medical Devices industry.

( Industry Median: 12.55 vs. ZMH: 40.08 )
ZMH' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 35.43   Max: 78.55
Current: 40.08

35.43
78.55
Revenue Growth (%) 8.60
ZMH's Revenue Growth (%) is ranked higher than
78% of the 278 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. ZMH: 8.60 )
ZMH' s 10-Year Revenue Growth (%) Range
Min: 8.6   Max: 25.6
Current: 8.6

8.6
25.6
EBITDA Growth (%) 9.40
ZMH's EBITDA Growth (%) is ranked higher than
84% of the 249 Companies
in the Global Medical Devices industry.

( Industry Median: -3.70 vs. ZMH: 9.40 )
ZMH' s 10-Year EBITDA Growth (%) Range
Min: 3.1   Max: 39.6
Current: 9.4

3.1
39.6
EPS Growth (%) 14.30
ZMH's EPS Growth (%) is ranked higher than
85% of the 233 Companies
in the Global Medical Devices industry.

( Industry Median: -2.80 vs. ZMH: 14.30 )
ZMH' s 10-Year EPS Growth (%) Range
Min: -3.1   Max: 41.7
Current: 14.3

-3.1
41.7
» ZMH's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

ZMH Guru Trades in Q1 2013

Pioneer Investments 343,910 sh (New)
Jim Simons 146,400 sh (New)
Scott Black 74,852 sh (+80.89%)
Paul Tudor Jones 9,700 sh (+64.41%)
HOTCHKIS & WILEY 1,832,200 sh (+10.69%)
Ken Fisher 179,315 sh (+6.94%)
Vanguard Health Care Fund 2,400,000 sh (unchged)
Jean-Marie Eveillard 1,632 sh (unchged)
Jeff Auxier 97,852 sh (unchged)
Bill Frels 704,175 sh (-1.6%)
Mario Gabelli 338,352 sh (-2.1%)
Private Capital 309,839 sh (-5.16%)
John Rogers 1,216,061 sh (-5.86%)
David Dreman 47,242 sh (-6.16%)
PRIMECAP Management 484,300 sh (-6.47%)
Jeremy Grantham 4,187,978 sh (-8.69%)
Robert Olstein 91,000 sh (-14.15%)
Ray Dalio 53,794 sh (-35.95%)
John Hussman 250,000 sh (-50%)
Joel Greenblatt 26,313 sh (-54.48%)
» More
Q2 2013

ZMH Guru Trades in Q2 2013

Steven Cohen 180,387 sh (New)
Jim Simons 371,100 sh (+153.48%)
Scott Black 140,668 sh (+87.93%)
Ray Dalio 61,550 sh (+14.42%)
Pioneer Investments 346,750 sh (+0.83%)
David Dreman 47,274 sh (+0.07%)
Jean-Marie Eveillard 1,632 sh (unchged)
Robert Olstein 91,000 sh (unchged)
Vanguard Health Care Fund 2,400,000 sh (unchged)
Jeff Auxier 97,852 sh (unchged)
Stanley Druckenmiller Sold Out
HOTCHKIS & WILEY 1,829,063 sh (-0.17%)
Ken Fisher 177,935 sh (-0.77%)
Bill Frels 695,522 sh (-1.23%)
PRIMECAP Management 477,300 sh (-1.45%)
Private Capital 302,454 sh (-2.38%)
Mario Gabelli 329,152 sh (-2.72%)
Paul Tudor Jones 8,600 sh (-11.34%)
John Hussman 200,000 sh (-20%)
Jeremy Grantham 3,295,090 sh (-21.32%)
John Rogers 880,911 sh (-27.56%)
Joel Greenblatt 15,959 sh (-39.35%)
» More
Q3 2013

ZMH Guru Trades in Q3 2013

Paul Tudor Jones 309,400 sh (+3497.67%)
Steven Cohen 391,638 sh (+117.11%)
John Rogers 910,624 sh (+3.37%)
Ken Fisher 181,535 sh (+2.02%)
Jean-Marie Eveillard 1,632 sh (unchged)
Jeff Auxier 97,852 sh (unchged)
HOTCHKIS & WILEY 1,826,163 sh (-0.16%)
PRIMECAP Management 463,600 sh (-2.87%)
Mario Gabelli 317,352 sh (-3.58%)
Bill Frels 669,587 sh (-3.73%)
Private Capital 290,755 sh (-3.87%)
Vanguard Health Care Fund 2,294,900 sh (-4.38%)
Scott Black 133,641 sh (-5%)
Robert Olstein 76,000 sh (-16.48%)
Jeremy Grantham 2,539,239 sh (-22.94%)
Pioneer Investments 259,550 sh (-25.15%)
Joel Greenblatt 5,550 sh (-65.22%)
John Hussman 56,000 sh (-72%)
Jim Simons 70,000 sh (-81.14%)
Ray Dalio 10,492 sh (-82.95%)
David Dreman 1,229 sh (-97.4%)
» More
Q4 2013

ZMH Guru Trades in Q4 2013

RS Investment Management 49,400 sh (New)
Pioneer Investments 312,886 sh (+20.55%)
John Rogers 928,760 sh (+1.99%)
Jean-Marie Eveillard 1,632 sh (unchged)
John Hussman Sold Out
Jim Simons Sold Out
Jeff Auxier 97,802 sh (-0.05%)
Mario Gabelli 315,502 sh (-0.58%)
Bill Frels 663,084 sh (-0.97%)
PRIMECAP Management 457,300 sh (-1.36%)
Ken Fisher 178,645 sh (-1.59%)
Scott Black 128,824 sh (-3.6%)
Vanguard Health Care Fund 2,146,200 sh (-6.48%)
Robert Olstein 71,000 sh (-6.58%)
Jeremy Grantham 2,287,917 sh (-9.9%)
HOTCHKIS & WILEY 1,521,304 sh (-16.69%)
Steven Cohen 314,523 sh (-19.69%)
Ray Dalio 6,792 sh (-35.26%)
Paul Tudor Jones 183,700 sh (-40.63%)
Private Capital 158,125 sh (-45.62%)
Joel Greenblatt 2,691 sh (-51.51%)
David Dreman 340 sh (-72.34%)
» More
» Details

Insider Trades

Latest Guru Trades with ZMH

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Hussman 2013-12-31 Sold Out 0.25%$82.66 - $93.43 $ 90.992%0
Joel Greenblatt 2013-12-31 Reduce -51.51%0.01%$82.66 - $93.43 $ 90.992%2691
David Dreman 2013-12-31 Reduce -72.34%0.01%$82.66 - $93.43 $ 90.992%340
Ray Dalio 2013-12-31 Reduce -35.26%$82.66 - $93.43 $ 90.992%6792
John Hussman 2013-09-30 Reduce -72%0.49%$75.42 - $84.67 $ 90.9912%56000
David Dreman 2013-09-30 Reduce -97.4%0.11%$75.42 - $84.67 $ 90.9912%1229
Ray Dalio 2013-09-30 Reduce -82.95%0.03%$75.42 - $84.67 $ 90.9912%10492
Joel Greenblatt 2013-09-30 Reduce -65.22%0.03%$75.42 - $84.67 $ 90.9912%5550
Scott Black 2013-06-30 Add 87.93%0.61%$72.97 - $81.01 $ 90.9918%140668
John Hussman 2013-06-30 Reduce -20%0.14%$72.97 - $81.01 $ 90.9918%200000
Joel Greenblatt 2013-06-30 Reduce -39.35%0.04%$72.97 - $81.01 $ 90.9918%15959
John Hussman 2013-03-31 Reduce -50%0.44%$66.66 - $76.34 $ 90.9924%250000
Scott Black 2013-03-31 Add 80.89%0.32%$66.66 - $76.34 $ 90.9924%74852
Joel Greenblatt 2013-03-31 Reduce -54.48%0.12%$66.66 - $76.34 $ 90.9924%26313
Ray Dalio 2013-03-31 Reduce -35.95%0.02%$66.66 - $76.34 $ 90.9924%53794
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 20.50
ZMH's P/E(ttm) is ranked higher than
80% of the 231 Companies
in the Global Medical Devices industry.

( Industry Median: 26.70 vs. ZMH: 20.50 )
ZMH' s 10-Year P/E(ttm) Range
Min: 9.08   Max: 61.06
Current: 20.5

9.08
61.06
P/B 2.50
ZMH's P/B is ranked higher than
66% of the 355 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. ZMH: 2.50 )
ZMH' s 10-Year P/B Range
Min: 1.31   Max: 21.4
Current: 2.5

1.31
21.4
P/S 3.40
ZMH's P/S is ranked lower than
55% of the 372 Companies
in the Global Medical Devices industry.

( Industry Median: 2.74 vs. ZMH: 3.40 )
ZMH' s 10-Year P/S Range
Min: 1.82   Max: 8.95
Current: 3.4

1.82
8.95
PFCF 23.50
ZMH's PFCF is ranked higher than
67% of the 179 Companies
in the Global Medical Devices industry.

( Industry Median: 27.48 vs. ZMH: 23.50 )
ZMH' s 10-Year PFCF Range
Min: 9.54   Max: 50.48
Current: 23.5

9.54
50.48
EV-to-EBIT 14.90
ZMH's EV-to-EBIT is ranked higher than
77% of the 293 Companies
in the Global Medical Devices industry.

( Industry Median: 20.91 vs. ZMH: 14.90 )
ZMH' s 10-Year EV-to-EBIT Range
Min: 6.8   Max: 45.8
Current: 14.9

6.8
45.8
PEG 2.60
ZMH's PEG is ranked higher than
70% of the 119 Companies
in the Global Medical Devices industry.

( Industry Median: 2.53 vs. ZMH: 2.60 )
ZMH' s 10-Year PEG Range
Min: 0.44   Max: 5.43
Current: 2.6

0.44
5.43
Shiller P/E 23.00
ZMH's Shiller P/E is ranked higher than
77% of the 141 Companies
in the Global Medical Devices industry.

( Industry Median: 27.00 vs. ZMH: 23.00 )
ZMH' s 10-Year Shiller P/E Range
Min: 10.71   Max: 39.22
Current: 23

10.71
39.22

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.90
ZMH's Dividend Yield is ranked lower than
61% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 1.28 vs. ZMH: 0.90 )
ZMH' s 10-Year Dividend Yield Range
Min: 0.28   Max: 1.1
Current: 0.9

0.28
1.1
Dividend Payout 0.18
ZMH's Dividend Payout is ranked higher than
84% of the 140 Companies
in the Global Medical Devices industry.

( Industry Median: 0.35 vs. ZMH: 0.18 )
ZMH' s 10-Year Dividend Payout Range
Min: 0.17   Max: 0.18
Current: 0.18

0.17
0.18
Yield on cost (5-Year) 0.90
ZMH's Yield on cost (5-Year) is ranked lower than
64% of the 168 Companies
in the Global Medical Devices industry.

( Industry Median: 1.39 vs. ZMH: 0.90 )
ZMH' s 10-Year Yield on cost (5-Year) Range
Min: 0.28   Max: 1.1
Current: 0.9

0.28
1.1
Share Buyback Rate 5.10
ZMH's Share Buyback Rate is ranked higher than
98% of the 270 Companies
in the Global Medical Devices industry.

( Industry Median: -1.30 vs. ZMH: 5.10 )
ZMH' s 10-Year Share Buyback Rate Range
Min: 6.6   Max: -8.4
Current: 5.1

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 5.30
ZMH's Price/Tangible Book is ranked lower than
54% of the 328 Companies
in the Global Medical Devices industry.

( Industry Median: 4.40 vs. ZMH: 5.30 )
ZMH' s 10-Year Price/Tangible Book Range
Min: 4.44   Max: 185.26
Current: 5.3

4.44
185.26
Price/DCF (Projected) 1.10
ZMH's Price/DCF (Projected) is ranked higher than
87% of the 177 Companies
in the Global Medical Devices industry.

( Industry Median: 1.90 vs. ZMH: 1.10 )
ZMH' s 10-Year Price/DCF (Projected) Range
Min: 0.65   Max: 1.64
Current: 1.1

0.65
1.64
Price/Median PS Value 1.00
ZMH's Price/Median PS Value is ranked higher than
73% of the 338 Companies
in the Global Medical Devices industry.

( Industry Median: 1.10 vs. ZMH: 1.00 )
ZMH' s 10-Year Price/Median PS Value Range
Min: 0.63   Max: 2.24
Current: 1

0.63
2.24
Price/Peter Lynch Fair Value 2.70
ZMH's Price/Peter Lynch Fair Value is ranked higher than
54% of the 59 Companies
in the Global Medical Devices industry.

( Industry Median: 1.80 vs. ZMH: 2.70 )
ZMH' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.66   Max: 2.8
Current: 2.7

0.66
2.8
Price/Graham Number 2.20
ZMH's Price/Graham Number is ranked higher than
61% of the 213 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. ZMH: 2.20 )
ZMH' s 10-Year Price/Graham Number Range
Min: 1.47   Max: 22.07
Current: 2.2

1.47
22.07
Earnings Yield (Greenblatt) 6.70
ZMH's Earnings Yield (Greenblatt) is ranked higher than
80% of the 279 Companies
in the Global Medical Devices industry.

( Industry Median: 4.60 vs. ZMH: 6.70 )
ZMH' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.2   Max: 14.7
Current: 6.7

2.2
14.7
Forward Rate of Return (Yacktman) 11.22
ZMH's Forward Rate of Return (Yacktman) is ranked higher than
91% of the 259 Companies
in the Global Medical Devices industry.

( Industry Median: 1.31 vs. ZMH: 11.22 )
ZMH' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 8.9   Max: 43.4
Current: 11.22

8.9
43.4

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, STJ, EW » details
Traded in other countries:ZMH.Switzerland, ZIM.Germany
Zimmer Holdings, Inc., a Delaware corporation was incorporated in 2001. The Company designs, develops, manufactures and markets orthopaedic reconstructive, spinal and trauma devices, biologics, dental implants and related surgical products. It also provides other healthcare related services. It has operations in more than 25 countries and market products in more than 100 countries. The Company manages its operations through three major geographic segments - the Americas, which is comprised principally of the United States and includes other North, Central and South American markets; Europe, which is comprised principally of Europe and includes the Middle East and Africa; and Asia Pacific, which is comprised mainly of Japan and Australia and includes other Asian and Pacific markets. It markets and sells products through three principal channels: direct to healthcare institutions, such as hospitals or direct channel accounts; through stocking distributors and healthcare dealers and directly to dental practices and dental laboratories. The Company's products include orthopaedic reconstructive implants, spinal and trauma devices, biologics, dental implants and related surgical products. Orthopaedic reconstructive implants include Knee Implants, Hip Implants and Extremity implants. Total knee replacement surgeries typically include a femoral component, a patella a tibial tray and an articular surface. Total hip replacement surgeries replace both the head of the femur and the socket portion of the pelvis of the natural hip. Its extremity portfolio, mainly shoulder and elbow products, is designed to treat arthritic conditions, soft tissue injuries and fractures, as well as to enhance the outcome of main or revision surgery. Trauma products include devices used to stabilize damaged or broken bones and their surrounding tissues to support the body's natural healing processes. Spine products division designs, manufactures and distributes medical devices and surgical instruments to deliver comprehensive solutions for those with back or neck pain caused by degenerative conditions, deformities or traumatic injury of the spine. The Company's Biologics group based in Austin, Texas works on biological solutions to repair and regenerate damaged or degenerated musculoskeletal tissues using biomaterials/cell therapies which offer the possibility of treating damaged joints by biological repair rather than replacing them. The Company's dental products division manufactures and distributes: dental reconstructive implants - for individuals who are totally without teeth or are missing one or more teeth; dental restorative products - aimed at providing a more natural restoration to mimic the original teeth and dental regenerative products - for soft tissue and bone rehabilitation. The Company develops, manufactures and markets products that support its reconstructive, trauma, spine and dental implant procedures, with a focus on bone cements, surgical wou

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide